文献速递白血病造血干细胞移植与细胞治疗

DLK1是GATA1s驱动的唐氏综合征相关髓系白血病的依赖因子和治疗靶点

DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia.
PubMed 文献 · Blood Adv · 2026-01-01

唐氏综合征相关髓系白血病(ML-DS)与GATA1s突变相关,复发难治者生存差。研究发现DLK1是GATA1s直接靶点,在胎儿造血高表达而成人造血缺失。遗传敲除DLK1损害增殖和移植、诱导凋亡;DLK1抗体药物偶联物在PDX模型中显示选择性细胞毒并延长生存。

要点

  • DLK1是GATA1s直接靶点,在ML-DS中异常高表达。
  • DLK1遗传敲除损害白血病增殖、移植并诱导凋亡。
  • DLK1抗体药物偶联物在PDX模型中延长生存并实现持久缓解。

核心结论

  • DLK1是ML-DS的白血病特异性脆弱点,为DLK1靶向治疗提供临床前概念验证。

研究设计与样本

  • 研究整合染色质分析、功能遗传学及患者来源异种移植(PDX)模型。

主要发现

  • 染色质分析显示GATA1s占据DLK1-DIO3位点远端增强子,驱动ML-DS中DLK1异常上调。
  • DLK1遗传敲除损害增殖和移植、诱导凋亡并改变Notch和β-catenin信号。
  • DLK1抗体药物偶联物诱导选择性细胞毒、消除集落形成,在难治ML-DS PDX模型中显著延长生存,高剂量实现持久缓解。

临床怎么用

  • DLK1可作为ML-DS及其他具有胎儿样表达程序白血病的潜在免疫治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children with Down syndrome have a markedly increased risk of developing myeloid leukemia. Although having an excellent prognosis, 10% to 20% develop relapsed or refractory disease with poor survival, highlighting the need for new targeted approaches. The pathogenesis of myeloid leukemia of Down syndrome (ML-DS) is tightly linked to fetal hematopoiesis and mutations in GATA1, generating the truncated GATA1 short (GATA1s) isoform. We identified Delta-like noncanonical Notch ligand 1 (DLK1) as a direct GATA1s target. DLK1, a paternally imprinted transmembrane protein, is highly expressed in fetal liver CD34+ cells but absent in adult hematopoiesis, making it an attractive immunotherapeutic target. Chromatin profiling revealed GATA1s occupancy at a distal enhancer within the DLK1-DIO3 locus, driving aberrant DLK1 upregulation in ML-DS. Functional studies demonstrated that DLK1 is a leukemia dependency, as its genetic ablation impaired proliferation and engraftment, induced apoptosis, and altered Notch and β-catenin signaling. Therapeutically, a DLK1-directed antibody-drug conjugate-induced selective cytotoxicity, abrogated colony formation, and significantly prolonged survival in refractory ML-DS patient-derived xenograft (PDX) models, achieving durable remissions at higher doses. These findings establish DLK1 as a leukemia-specific vulnerability and provide preclinical proof-of-concept for DLK1-targeted therapies in ML-DS and other leukemias with fetal-like expression programs.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Verboon LJ, Barwe SP, Tavenner M, et al. DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia. Blood Adv. 2026. PMID: 41945753. doi:10.1182/bloodadvances.2025018830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。